Viridian Therapeutics, Inc.\DE (VRDN) Income towards Parent Company (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Income towards Parent Company history runs 14 years deep, the most recent figure standing at -$111.8 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 18.69% year-over-year to -$111.8 million in Q1 2026; TTM through Mar 2026 was -$357.5 million, a 5.86% decrease from a year earlier, with the FY2025 full-year figure at -$652.8 million, down 37.16% from the prior year.
• Income towards Parent Company eased to -$111.8 million in Q1 2026 per VRDN's latest filing, from -$99.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$25.7 million in Q1 2022 and bottomed at -$111.8 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$68.2 million (2023), against an average of -$66.9 million.
• Across the five-year window, Income towards Parent Company plunged 165.39% in 2023 and surged 61.69% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$45.6 million in 2022, then slumped by 84.64% to -$84.2 million in 2023, then climbed by 6.04% to -$79.1 million in 2024, then retreated by 25.18% to -$99.0 million in 2025, then retreated by 12.88% to -$111.8 million in 2026.
• Per Business Quant, the three latest VRDN Income towards Parent Company figures stand at -$111.8 million (Q1 2026), -$99.0 million (Q4 2025), and -$35.1 million (Q3 2025).